Comparative Pharmacology
Head-to-head clinical analysis: BENZNIDAZOLE versus NITAZOXANIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZNIDAZOLE versus NITAZOXANIDE.
BENZNIDAZOLE vs NITAZOXANIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benznidazole is a nitroimidazole derivative that exerts trypanocidal activity against Trypanosoma cruzi. Its mechanism involves the reduction of the nitro group by a nitroreductase enzyme in the parasite, leading to the generation of toxic metabolites that damage parasite DNA and other cellular components.
Interferes with pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reactions, essential for anaerobic metabolism in certain pathogens.
5-7 mg/kg/day orally divided into two daily doses for 60 days. Maximum daily dose: 300 mg.
500 mg orally twice daily for 3 days for treatment of diarrhea caused by Cryptosporidium parvum or Giardia lamblia; for chronic giardiasis, 500 mg twice daily for 10 days.
None Documented
None Documented
Clinical Note
moderateBenznidazole + Leflunomide
"The risk or severity of adverse effects can be increased when Benznidazole is combined with Leflunomide."
Clinical Note
moderateBenznidazole + Fingolimod
"Benznidazole may increase the immunosuppressive activities of Fingolimod."
Clinical Note
moderateBenznidazole + Tofacitinib
"Benznidazole may increase the immunosuppressive activities of Tofacitinib."
Clinical Note
moderatePimecrolimus + Benznidazole
Terminal elimination half-life is approximately 12 hours; may be prolonged in hepatic impairment.
The terminal elimination half-life of the active metabolite tizoxanide is approximately 1.5–2 hours in adults and 2–4 hours in children. Clinical context: The short half-life supports twice-daily dosing; accumulation is minimal with normal dosing intervals.
Primarily renal excretion of metabolites; <5% unchanged drug. Approximately 20% in feces.
Nitazoxanide is primarily excreted in feces (approximately 66%) and urine (approximately 33%). Renal elimination accounts for about 33% of the dose, primarily as the active metabolite tizoxanide (glucuronide conjugates), while fecal excretion accounts for approximately 66%, mostly as tizoxanide and its conjugates.
Category C
Category A/B
Antiprotozoal
Antiprotozoal
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Benznidazole."